HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bone morphogenetic protein 15 (BMP15) alleles predict over-response to recombinant follicle stimulation hormone and iatrogenic ovarian hyperstimulation syndrome (OHSS).

AbstractOBJECTIVE:
Controlled ovarian stimulation (COS) using recombinant follicle-stimulating hormone (rFSH) is the main treatment in assisted reproduction. We performed a pharmacogenetic analysis of bone morphogenetic protein 15 (BMP15) gene using single nucleotide polymorphisms (SNPs) in COS. We also investigated the role of the BMP15 gene in ovarian hyperstimulation syndrome (OHSS).
METHODS:
We analysed different intragenic SNPs located within the BMP15 gene in 307 women treated with rFSH, evaluating its involvement in COS outcome.
RESULTS:
First, we analysed two polymorphisms, by applying different tests for genetic association, and we found a minimum P-value in patients producing > or =12 follicles in COS (high responders) in both polymorphisms of the BMP15 gene. Using bi-directional DNA sequencing, we identified two additional single nucleotide DNA variants. Second, we conducted association studies with all polymorphisms together, and noticed that none of them seemed to fully explain the association of the BMP15 gene with over-response to rFSH. However, N103S missense mutation is predicted to disrupt the secondary structure of human BMP15 protein and is weakly associated with OHSS. This coding mutation of the BMP15 gene may partially explain the results obtained during our research. Using Thesias software, we reconstructed haplotypes with the four intragenic variants and calculated their frequencies in normal and over-responders to rFSH. The haplotype TGGA was over-represented in high responders when compared with the rest of patients. Moreover, this association was higher in patients with OHSS, with a significant global haplotypic effect of the BMP15 gene.
CONCLUSION:
Our results suggest a direct relationship between increased follicle production during COS and BMP15 alleles in response to rFSH in humans. The use of BMP15 markers to prevent OHSS is also a possibility that requires thorough evaluation.
AuthorsFrancisco J Morón, Francisco de Castro, Jose L Royo, Luis Montoro, Emilia Mira, María E Sáez, Luis M Real, Alejandro González, Santos Mañes, Agustín Ruiz
JournalPharmacogenetics and genomics (Pharmacogenet Genomics) Vol. 16 Issue 7 Pg. 485-95 (Jul 2006) ISSN: 1744-6872 [Print] United States
PMID16788381 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • BMP15 protein, human
  • Bone Morphogenetic Protein 15
  • GDF9 protein, human
  • Growth Differentiation Factor 9
  • Intercellular Signaling Peptides and Proteins
  • Recombinant Proteins
  • Follicle Stimulating Hormone
Topics
  • Adult
  • Alleles
  • Bone Morphogenetic Protein 15
  • Female
  • Fertilization in Vitro
  • Follicle Stimulating Hormone (adverse effects, therapeutic use)
  • Growth Differentiation Factor 9
  • Humans
  • Iatrogenic Disease
  • Intercellular Signaling Peptides and Proteins (genetics)
  • Ovarian Hyperstimulation Syndrome (chemically induced, etiology, genetics)
  • Ovulation Induction (adverse effects, methods)
  • Polymorphism, Single Nucleotide
  • Predictive Value of Tests
  • Recombinant Proteins
  • Retrospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: